Masp2 Antibody

What is MASP2 and what is its role in the complement system?

MASP2 (mannose-binding lectin associated serine protease 2) is a trypsin-like serine protease that plays a crucial role in the initiation of the mannose-binding lectin (MBL) complement activation pathway. The complement system can be activated through three distinct pathways: the antibody-dependent classical pathway, the antibody-independent alternative pathway, and the lectin pathway. In each pathway, activation involves the formation of serine protease complexes that ultimately lead to the activation of complement component C3 .

In the lectin pathway specifically, MASP2 forms complexes with polymeric lectin molecules that recognize particular carbohydrate patterns. When these recognition molecules bind to carbohydrates on microbial surfaces, MASP2 converts to its active form and initiates complement activation. MASP2 functions by cleaving complement components C4 and C2, which is essential for the activation of downstream complement components in the pathway .

What is the relationship between MASP2 and MAp19, and how can antibodies distinguish between them?

MAp19 is an alternative splicing product of the MASP2 gene. Structurally, MAp19 comprises the first two domains of MASP2 followed by a unique C-terminal sequence of four amino acids (EQSL). Both MASP2 and MAp19 can bind to mannose-binding lectin (MBL) in a calcium-dependent manner .

When selecting antibodies for research, it's important to note that some antibodies, like the monoclonal antibody 6G12, react with both human MASP2 and human MAp19. This is because such antibodies target the N-terminal end of MASP2, which is shared with MAp19. In western blot applications, researchers can distinguish between the two proteins based on their molecular weights: MASP2 has an expected band size of approximately 75 kDa, while MAp19 appears at approximately 20 kDa .

When designing experiments requiring selective detection of either MASP2 or MAp19, researchers should carefully review the antibody's epitope specificity. Antibodies targeting regions unique to MASP2 (not present in MAp19) would be appropriate for MASP2-specific detection.

What are the recommended experimental conditions for detecting MASP2 via western blotting?

For western blot detection of MASP2, both reduced and non-reduced conditions can be employed. The expected band size for MASP2 is approximately 75 kDa, while MAp19 appears at approximately 20 kDa . Based on available product information, several anti-MASP2 antibodies have been validated for western blot applications .

When optimizing western blot protocols for MASP2 detection, consider the following methodological recommendations:

• Sample preparation: Protein extraction from cells or tissues should be performed using lysis buffers containing protease inhibitors to prevent degradation of MASP2.

• Loading controls: Include appropriate loading controls based on your sample type.

• Blocking: Use 5% non-fat dry milk or BSA in TBST for blocking non-specific binding sites.

• Primary antibody incubation: Optimize antibody dilution (typically 1:500 to 1:2000) and incubation time (overnight at 4°C is often effective).

• Secondary antibody selection: Choose a secondary antibody that specifically recognizes the isotype of your primary anti-MASP2 antibody.

• Signal detection: Both chemiluminescent and fluorescent detection methods are suitable; select based on your laboratory's available equipment.

How do MASP2 levels vary in different thrombotic microangiopathies, and what methods are most reliable for measurement?

Research has demonstrated that MASP2 levels are significantly elevated in different forms of thrombotic microangiopathies (TMAs). In a comparative study, MASP2 concentrations were measured in patients with thrombotic thrombocytopenic purpura (TTP), atypical hemolytic uremic syndrome (aHUS), and hematopoietic stem cell transplantation-associated TMA (HSCT-TMA) .

The results showed marked elevation of MASP2 across these conditions compared to healthy controls:

For reliable measurement of MASP2 levels in clinical samples, enzyme-linked immunosorbent assay (ELISA) techniques have been validated. When establishing MASP2 quantification protocols, researchers should:

• Collect plasma samples using standardized procedures to ensure consistent results.

• Process samples promptly to prevent degradation of complement proteins.

• Include appropriate calibrators and controls in each assay.

• Consider potential interferents in patient samples, particularly in those with inflammatory conditions.

• Validate the linearity and precision of the assay across the expected concentration range.

What is the mechanism of action for narsoplimab, and how can its inhibitory activity be assessed?

Narsoplimab (OMS721) is a fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody specifically developed to bind to MASP2 and inhibit lectin pathway activation. Understanding its mechanism and measuring its efficacy requires sophisticated experimental approaches .

The binding affinity of narsoplimab to MASP2 can be assessed using ELISA methods. In these assays, plates are coated with recombinant human MASP2 as the antigen, followed by incubation with serially diluted narsoplimab or its Fab fragment. After washing, bound antibody is detected using an enzyme-conjugated anti-human IgG antibody and appropriate substrate. The binding constant (K) can be estimated by fitting the binding dose-response data to a 4-parameter logistic model .

The functional potency of MASP2 inhibition by narsoplimab can be determined by measuring its ability to inhibit C3 or C4 activation. The inhibitory concentration (IC50) is estimated by plotting absorbance values (from ELISA) or mean fluorescent intensity values (from flow cytometry) against antibody concentration, then fitting the data to a 4-parameter logistic regression .

For flow cytometry-based assessment of C4 activation inhibition, the methodology involves:

• Incubating beads with biotinylated antibodies specific to C4 (the species of antibody depends on the experimental model - anti-mouse C4 for mice, biotinylated chicken anti-human C4 for rabbits, and mouse anti-human C4d monoclonal antibody for humans and monkeys).

• Measuring the reduced C4 deposition in the presence of varying concentrations of narsoplimab.

• Calculating the IC50 from the resulting inhibition curve .

How can researchers troubleshoot non-specific binding when using anti-MASP2 antibodies?

Non-specific binding is a common challenge when working with antibodies, including those targeting MASP2. Researchers can implement several methodological approaches to reduce non-specific binding and improve experimental outcomes:

• Optimize blocking conditions: Test different blocking agents (BSA, normal serum, commercial blocking buffers) and concentrations to identify the optimal formulation for your specific anti-MASP2 antibody.

• Increase washing stringency: Additional or longer washing steps with appropriate buffers can help reduce non-specific binding. For western blots, consider increasing the concentration of Tween-20 in wash buffers (up to 0.1%).

• Titrate primary antibody: Determine the minimum effective concentration of anti-MASP2 antibody needed for specific detection. This often helps reduce background without compromising specific signal.

• Include appropriate controls:

  • Negative controls (samples known to be negative for MASP2)

  • Isotype controls (non-specific antibody of the same isotype as the anti-MASP2 antibody)

  • Peptide competition assays (pre-incubating the antibody with excess MASP2 peptide)

• Pre-adsorb antibody: For cross-reactive antibodies, consider pre-adsorbing against proteins or tissues known to cause cross-reactivity.

• Consider detection system modifications: For particularly challenging applications, switching between direct and indirect detection methods, or between enzymatic and fluorescent detection systems, may improve specificity.

What sample preparation methods are optimal for preserving MASP2 integrity in different biological specimens?

MASP2 is a complement protein that requires careful handling to maintain its integrity during sample preparation. The optimal sample preparation methods vary depending on the biological specimen and the intended analytical technique.

For plasma and serum samples:

• Collect blood in appropriate anticoagulant tubes (EDTA or citrate for plasma, or serum separator tubes).

• Process samples promptly (within 30-60 minutes of collection) to minimize complement activation.

• Centrifuge at 2000-3000 × g for 10-15 minutes at 4°C.

• Aliquot and store at -80°C to prevent freeze-thaw cycles.

• Include protease inhibitors (e.g., PMSF, aprotinin, leupeptin) if samples cannot be processed immediately.

For tissue samples (immunohistochemistry applications):

• Use freshly collected tissues whenever possible or properly flash-frozen samples.

• For formalin-fixed, paraffin-embedded tissues, optimize antigen retrieval methods (heat-induced epitope retrieval in citrate buffer, pH 6.0, or EDTA buffer, pH 8.0).

• Consider the impact of fixation time on epitope accessibility.

• Test multiple antibody dilutions to determine optimal staining conditions.

For cell culture samples:

• Harvest cells at 70-80% confluence to ensure consistent protein expression.

• Wash cells thoroughly with cold PBS to remove media components.

• Use lysis buffers compatible with downstream applications (RIPA buffer for western blotting, gentler buffers for immunoprecipitation).

• Always include protease inhibitor cocktails in lysis buffers.

• Perform lysis on ice and process samples promptly.

What species cross-reactivity patterns should researchers consider when selecting anti-MASP2 antibodies?

When designing comparative studies across different species, researchers must carefully evaluate the cross-reactivity patterns of anti-MASP2 antibodies. Based on product information for commercially available antibodies, reactivity varies considerably .

Most anti-MASP2 antibodies are raised against human MASP2, but some show cross-reactivity with orthologs from other species. When selecting antibodies for multi-species studies:

• Review vendor-provided cross-reactivity data: Many suppliers specify reactivity with human, mouse, rat, monkey, canine, and porcine MASP2 orthologs .

• Consider sequence homology: Higher sequence homology between species increases the likelihood of cross-reactivity. Human MASP2 shares approximately 83% sequence identity with non-human primates, 68% with mice, and 67% with rats.

• Validate antibodies for each species: Even when vendors claim cross-reactivity, independent validation is essential. This should include:

  • Positive controls (samples known to express MASP2 in each species)

  • Negative controls (MASP2-knockout or depleted samples if available)

  • Western blot analysis to confirm expected molecular weight

  • Immunoprecipitation followed by mass spectrometry to confirm specificity

• Consider epitope location: Antibodies targeting highly conserved domains (such as the serine protease domain) are more likely to work across species compared to those targeting more variable regions.

• For specialized applications like neutralization studies, functional validation across species is particularly important as binding does not always correlate with functional inhibition.

How can MASP2 antibodies contribute to biomarker development for thrombotic microangiopathies?

Elevated MASP2 levels have been observed in various thrombotic microangiopathies (TMAs), suggesting potential utility as a biomarker. Research has demonstrated significantly higher MASP2 concentrations in TTP patients (210.4 ng/ml), all non-TTP TMA patients (150.0 ng/ml), and HSCT-TMA patients (154.0 ng/ml) compared to healthy controls (70.8 ng/ml) .

For biomarker development, researchers should consider these methodological approaches:

• Standardized quantification: Develop or adopt standardized ELISA protocols using well-characterized anti-MASP2 antibodies. Ensure consistent sample handling to minimize pre-analytical variability.

• Reference interval establishment: Define age, sex, and ethnicity-specific reference intervals for MASP2 levels in healthy populations.

• Correlation with disease severity: Investigate the relationship between MASP2 levels and clinical parameters, disease progression, and treatment response.

• Comparative analysis: Assess MASP2 in relation to established TMA markers (e.g., ADAMTS13 activity, complement activation markers) to determine if MASP2 provides additional diagnostic or prognostic information.

• Longitudinal studies: Monitor MASP2 levels over time to evaluate its utility in predicting disease flares or treatment response.

• Multi-center validation: Validate findings across multiple centers to confirm the robustness of MASP2 as a biomarker.

• Point-of-care development: Explore the potential for developing rapid testing methods using anti-MASP2 antibodies for clinical settings.

What insights have been gained from therapeutic antibodies targeting MASP2, such as narsoplimab?

The development of narsoplimab (OMS721), a fully human IgG4 monoclonal antibody designed to bind MASP2 and inhibit lectin pathway activation, has provided valuable insights into MASP2 biology and therapeutic potential. This antibody has been studied in clinical settings, particularly for HSCT-associated TMA .

Key findings and methodological approaches from narsoplimab research include:

• Selective inhibition: Narsoplimab has demonstrated the ability to selectively inhibit the lectin pathway without affecting the classical or alternative complement pathways, highlighting the feasibility of pathway-specific complement inhibition.

• In vitro efficacy: The antibody has shown potent inhibition of C4 and C3 activation in various experimental systems, with measurable IC50 values that can be determined through ELISA or flow cytometry-based assays .

• Ex vivo pharmacodynamics: Studies in primates treated with narsoplimab have established protocols for assessing pharmacodynamic responses in vivo, providing a framework for similar studies in human clinical trials.

• Binding affinity characterization: Detailed binding studies, including ELISA methods using recombinant human MASP2 as antigen, have characterized the interaction between narsoplimab and MASP2. These methods involve coating plates with recombinant MASP2, adding serially diluted antibody, and detecting binding with enzyme-conjugated anti-human IgG antibodies .

• Endothelial protection: Research suggests that MASP2 inhibition with antibodies like narsoplimab may suppress activation of microvascular endothelial cells induced by TMA patient plasmas, representing a potential mechanism of therapeutic action.

How should researchers optimize immunohistochemistry protocols for MASP2 detection in different tissue types?

Optimizing immunohistochemistry (IHC) protocols for MASP2 detection requires careful consideration of tissue-specific factors and antibody characteristics. Several anti-MASP2 antibodies have been validated for IHC applications .

Recommended optimization approaches include:

• Tissue preparation:

  • Use freshly collected tissues when possible

  • For FFPE tissues, ensure consistent fixation time (24-48 hours in 10% neutral buffered formalin)

  • Section thickness should typically be 4-5 μm

• Antigen retrieval:

  • Test multiple methods: heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) or EDTA buffer (pH 8.0-9.0)

  • Optimize retrieval time and temperature (typically 95-100°C for 10-30 minutes)

• Antibody optimization:

  • Perform titration experiments to determine optimal antibody concentration

  • Test different incubation conditions (typically 1 hour at room temperature or overnight at 4°C)

  • Consider signal amplification systems for low-abundance targets

• Detection system selection:

  • For chromogenic detection, compare DAB, AEC, and other substrates

  • For fluorescence, evaluate direct labeling versus secondary antibody approaches

  • Consider multiplex staining to examine MASP2 in relation to other markers

• Validation controls:

  • Positive control tissues (liver is often used as it expresses MASP2)

  • Negative controls (omitting primary antibody)

  • Peptide competition controls

  • Comparison with tissues from knockout models (if available)

• Tissue-specific considerations:

  • For liver: Evaluate specificity of hepatocyte versus non-parenchymal cell staining

  • For kidney: Assess glomerular versus tubular staining patterns

  • For vascular tissues: Pay particular attention to endothelial staining

What advanced techniques can be used to study MASP2-protein interactions?

Understanding MASP2's interactions with other proteins is essential for elucidating its functions in health and disease. Several advanced techniques can be employed:

• Co-immunoprecipitation (Co-IP):

  • Use anti-MASP2 antibodies to pull down MASP2 along with interacting partners

  • Confirm results with reciprocal IP using antibodies against putative interacting proteins

  • Consider crosslinking approaches for transient interactions

  • Analyze precipitated complexes by western blot or mass spectrometry

• Proximity Ligation Assay (PLA):

  • This technique allows visualization of protein-protein interactions in situ

  • Requires two primary antibodies from different species (anti-MASP2 and antibody against potential interacting protein)

  • Species-specific secondary antibodies conjugated with oligonucleotides enable detection of proteins in close proximity (<40 nm)

  • Results in fluorescent dots representing interaction sites

• Bioluminescence Resonance Energy Transfer (BRET):

  • Tag MASP2 with a bioluminescent protein (e.g., Renilla luciferase)

  • Tag potential interacting proteins with fluorescent proteins (e.g., YFP)

  • Energy transfer occurs only when proteins interact, allowing quantitative assessment

• Surface Plasmon Resonance (SPR):

  • Immobilize purified MASP2 on a sensor chip

  • Flow potential interacting proteins over the surface

  • Measure association and dissociation rates to determine binding kinetics

  • This technique requires high-quality purified proteins

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

  • This technique identifies regions of MASP2 involved in protein-protein interactions

  • Compare hydrogen-deuterium exchange rates of MASP2 alone versus in complex with interacting proteins

  • Regions protected from exchange in the complex represent interaction interfaces

• Cryo-Electron Microscopy:

  • For structural characterization of MASP2 complexes

  • Particularly useful for larger assemblies like MASP2 with MBL or ficolins

  • Can provide near-atomic resolution of complex structures

For all these techniques, validation of antibody specificity is critical to ensure accurate interpretation of results.